King's College London

Research portal

Imaging Breast Cancer Bone Metastases: Current Status and Future Directions

Research output: Contribution to journalLiterature review

Standard

Imaging Breast Cancer Bone Metastases: Current Status and Future Directions. / Glendenning, Jennifer; Cook, Gary.

In: Seminars in Nuclear Medicine, Vol. 43, No. 4, 07.2013, p. 317-323.

Research output: Contribution to journalLiterature review

Harvard

Glendenning, J & Cook, G 2013, 'Imaging Breast Cancer Bone Metastases: Current Status and Future Directions', Seminars in Nuclear Medicine, vol. 43, no. 4, pp. 317-323. https://doi.org/10.1053/j.semnuclmed.2013.02.002

APA

Glendenning, J., & Cook, G. (2013). Imaging Breast Cancer Bone Metastases: Current Status and Future Directions. Seminars in Nuclear Medicine, 43(4), 317-323. https://doi.org/10.1053/j.semnuclmed.2013.02.002

Vancouver

Glendenning J, Cook G. Imaging Breast Cancer Bone Metastases: Current Status and Future Directions. Seminars in Nuclear Medicine. 2013 Jul;43(4):317-323. https://doi.org/10.1053/j.semnuclmed.2013.02.002

Author

Glendenning, Jennifer ; Cook, Gary. / Imaging Breast Cancer Bone Metastases: Current Status and Future Directions. In: Seminars in Nuclear Medicine. 2013 ; Vol. 43, No. 4. pp. 317-323.

Bibtex Download

@article{fdecc347ff72418eb1de148344534dd1,
title = "Imaging Breast Cancer Bone Metastases: Current Status and Future Directions",
abstract = "The skeleton is commonly affected in the context of metastatic breast cancer and is a cause of significant morbidity in these individuals. Therapeutic options include systemic therapy, radiotherapy, and surgery given with the intent of preserving function and quality of life. As the spectrum of available therapies increases, key challenges comprise reliable diagnosis of bony metastatic disease and accurate evaluation of response that permits rapid therapeutic transition in those responding inadequately prior to development of significant skeletal morbidity. The Tc-99m-diphosphonate bone scan remains one of the most commonly requested investigations for skeletal evaluation in patients with breast cancer. However a time lag of 3-6 months for accurate response evaluation from the start of treatment limits its utility for response evaluation in routine clinical practice or as a progression end point in the research setting. Functional imaging strategies using more tumor-specific radiopharmaceuticals show promise as an effective means of imaging response at a clinically relevant time point and are the subject of this review. (C) 2013 Elsevier Inc. All rights reserved.",
keywords = "POSITRON-EMISSION-TOMOGRAPHY, TREATMENT RESPONSE, F-18-FLUORIDE PET, TUMOR RESPONSE, PROGNOSTIC PARAMETERS, ESTROGEN-RECEPTORS, MONITOR TREATMENT, SYSTEMIC THERAPY, F-18-FDG PET/CT, PROSTATE-CANCER",
author = "Jennifer Glendenning and Gary Cook",
year = "2013",
month = jul,
doi = "10.1053/j.semnuclmed.2013.02.002",
language = "English",
volume = "43",
pages = "317--323",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "4",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Imaging Breast Cancer Bone Metastases: Current Status and Future Directions

AU - Glendenning, Jennifer

AU - Cook, Gary

PY - 2013/7

Y1 - 2013/7

N2 - The skeleton is commonly affected in the context of metastatic breast cancer and is a cause of significant morbidity in these individuals. Therapeutic options include systemic therapy, radiotherapy, and surgery given with the intent of preserving function and quality of life. As the spectrum of available therapies increases, key challenges comprise reliable diagnosis of bony metastatic disease and accurate evaluation of response that permits rapid therapeutic transition in those responding inadequately prior to development of significant skeletal morbidity. The Tc-99m-diphosphonate bone scan remains one of the most commonly requested investigations for skeletal evaluation in patients with breast cancer. However a time lag of 3-6 months for accurate response evaluation from the start of treatment limits its utility for response evaluation in routine clinical practice or as a progression end point in the research setting. Functional imaging strategies using more tumor-specific radiopharmaceuticals show promise as an effective means of imaging response at a clinically relevant time point and are the subject of this review. (C) 2013 Elsevier Inc. All rights reserved.

AB - The skeleton is commonly affected in the context of metastatic breast cancer and is a cause of significant morbidity in these individuals. Therapeutic options include systemic therapy, radiotherapy, and surgery given with the intent of preserving function and quality of life. As the spectrum of available therapies increases, key challenges comprise reliable diagnosis of bony metastatic disease and accurate evaluation of response that permits rapid therapeutic transition in those responding inadequately prior to development of significant skeletal morbidity. The Tc-99m-diphosphonate bone scan remains one of the most commonly requested investigations for skeletal evaluation in patients with breast cancer. However a time lag of 3-6 months for accurate response evaluation from the start of treatment limits its utility for response evaluation in routine clinical practice or as a progression end point in the research setting. Functional imaging strategies using more tumor-specific radiopharmaceuticals show promise as an effective means of imaging response at a clinically relevant time point and are the subject of this review. (C) 2013 Elsevier Inc. All rights reserved.

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - TREATMENT RESPONSE

KW - F-18-FLUORIDE PET

KW - TUMOR RESPONSE

KW - PROGNOSTIC PARAMETERS

KW - ESTROGEN-RECEPTORS

KW - MONITOR TREATMENT

KW - SYSTEMIC THERAPY

KW - F-18-FDG PET/CT

KW - PROSTATE-CANCER

U2 - 10.1053/j.semnuclmed.2013.02.002

DO - 10.1053/j.semnuclmed.2013.02.002

M3 - Literature review

VL - 43

SP - 317

EP - 323

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 4

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454